Document Detail


Baseline serum prolactin in drug-naive, first-episode schizophrenia and outcome at five years: is it a predictive factor?
MedLine Citation:
PMID:  22666637     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Serum prolactin is influenced by antipsychotic use but its relationships with psychopathology and general functioning are not clear. This study aimed to assess these relationships.
DESIGN: Serum prolactin levels were measured in patients with schizophrenia before being treated with antipsychotics and at various follow-up points.
SETTING: The study was conducted in a nongovernmental psychiatric treatment center in Mumbai, India.
PARTICIPANTS: The participants included 30 male and 30 female drug-naïve patients with schizophrenia and 31 control participants.
MEASUREMENTS: The severity of psychopathology at baseline, three weeks, six weeks, and five years following treatment was assessed using a modified Brief Psychiatric Rating Scale. The Global Assessment of Functioning questionnaire was used at baseline and five years follow up.
RESULTS: Contrary to our hypotheses, prolactin levels in male but not female patients at baseline were twice those of control volunteers. Correlations between prolactin, Brief Psychiatric Rating Scale, and Global Assessment of Functioning measurements were not significant for any time point up to six weeks, but were only significant at the five-year follow-up appointments, indicating that those patients with higher levels of serum prolactin had a better outcome at five years.
CONCLUSION: Baseline serum prolactin levels in drug-naive patients with schizophrenia may be used for long-term prognosis, but are not reliable indicators of psychopathology and prognosis in the short term. Future research is needed to conclude with confidence whether or not prolactin can be used as a biomarker of psychopathological and overall functioning in schizophrenia.
Authors:
Amresh Shrivastava; Megan Johnston; Yves Bureau; Nilesh Shah
Related Documents :
1971117 - Double blind, controlled study of the efficacy and safety of alpidem in the treatment o...
3406427 - Clinical correlations of one-carbon metabolism abnormalities.
10408267 - Symptom classification of schizophrenia changes with the duration of illness.
9353857 - Family interaction and the course of schizophrenic illness. results of a multivariate p...
23062747 - Effectiveness of a multi-component programme for managing depression in primary care: a...
22453707 - The effect of a herbal formulation on the incidence and severity of upper respiratory s...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Innovations in clinical neuroscience     Volume:  9     ISSN:  2158-8341     ISO Abbreviation:  Innov Clin Neurosci     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-06-05     Completed Date:  2013-01-10     Revised Date:  2014-08-06    
Medline Journal Info:
Nlm Unique ID:  101549695     Medline TA:  Innov Clin Neurosci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  17-21     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neurosarcoidosis and the complexity in its differential diagnoses: a review.
Next Document:  Physician grief with patient death.